Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lifted by Financial Partners Group LLC

Financial Partners Group LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 31.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 14,384 shares of the company’s stock after acquiring an additional 3,438 shares during the quarter. Financial Partners Group LLC’s holdings in Novo Nordisk A/S were worth $1,237,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of NVO. International Assets Investment Management LLC increased its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $98,765,000. Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,017,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $41,646,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.0 %

Shares of Novo Nordisk A/S stock opened at $81.36 on Friday. The firm has a market cap of $365.09 billion, a price-to-earnings ratio of 26.33, a P/E/G ratio of 0.90 and a beta of 0.45. The stock has a 50-day simple moving average of $96.10 and a 200-day simple moving average of $115.79. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NVO. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.